Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1178 | Cosentyx Wiki | 1.00 |
| drug4910 | ctDNA blood sampling Wiki | 1.00 |
| drug904 | Candin Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D046152 | Gastrointestinal Stromal Tumors NIH | 1.00 |
| D001661 | Biliary Tract Neoplasms NIH | 1.00 |
| D001749 | Urinary Bladder Neoplasms NIH | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100723 | Gastrointestinal stroma tumor HPO | 1.00 |
| HP:0100574 | Biliary tract neoplasm HPO | 1.00 |
| HP:0100834 | Neoplasm of the large intestine HPO | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100526 | Neoplasm of the lung HPO | 0.25 |
| HP:0002664 | Neoplasm HPO | 0.15 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to investigate the feasibility of using ctDNA to support cancer diagnosis and risk stratification where invasive aerosol generating testing (and/or tissue biopsy) is challenging due to infection risk, technical impracticalities and resource limitations, such as during the COVID-19 pandemic and the subsequent recovery period.
Description: The primary endpoint, ctDNA detection rate, overall and within different cancer types will be presented as a proportion of patients with a positive ctDNA test out of those tested, with 90% confidence intervals
Measure: ctDNA detection rate within different cancer types (and overall) Time: Throughout study completion, up to one yearDescription: All secondary endpoints will be analysed in the patients diagnosed with suspected cancer, i.e. positive ctDNA result, unless stated. They will also be presented overall and by cancer type. The proportion of patients with positive ctDNA result which identified a diagnosis and/or commenced treatment will be presented as a proportion with 90% confidence intervals
Measure: Proportion of patients with a positive ctDNA result which identified a diagnosis and/or commenced treatment Time: Throughout study completion, up to one yearDescription: Proportion of patients with positive ctDNA result which assisted in prioritising invasive diagnostic tests will be presented as a proportion with 90% confidence intervals
Measure: Proportion of patients with a positive ctDNA result which assisted in prioritising invasive diagnostic tests Time: Throughout study completion, up to one yearDescription: The association between ctDNA result (positive versus negative) and the PREVAIL-imaging pathway scoring result will be assessed descriptively by presenting cross-tabulations and relevant proportions
Measure: The association of ctDNA result (positive versus negative) and the PREVAIL-imaging pathway scoring result Time: Throughout study completion, up to one yearDescription: Simple estimation of the cost of liquid biopsy in lieu of tissue biopsy as compared to standard of care investigations and treatments prioritisation will be performed
Measure: Estimation of the cost of liquid biopsy in lieu of tissue biopsy as compared to standard of care investigations and treatments prioritisation Time: Throughout study completion, up to one yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports